Improving Preventive Laboratory Care for Individuals with Autism Spectrum Disorder: A Public Health Framework for Reducing Diagnostic and Health Disparities

Abstract

Ozioma Jerry Gabriel

Background: Autistic individuals across the lifespan experience significant physical multimorbidities, co-occurring psychiatric conditions, and elevated rates of psychotropic pharmacotherapy, particularly second-generation atypical antipsychotics and mood stabilizers. Although mandatory clinical laboratory monitoring—including fasting plasma glucose, lipid profiles, complete blood counts, hepatic/renal function panels, and therapeutic drug levels is legally and clinically mandated to prevent severe metabolic syndrome and end-organ toxicity, routine phlebotomy represents a critical pre-analytical barrier. Sensory hypersensitivities, hyperacusis, tactile defensiveness, needle fear, and rigid clinical environments trigger acute procedural distress, frequently resulting in failed blood draws, unmonitored drug regimens, procedure abandonment, or physical restraint, thereby exacerbating severe health disparities and premature mortality. Objectives: To systematically synthesize multi-disciplinary literature on pre-analytical phlebotomy barriers, metabolic monitoring compliance, and procedural accommodation strategies for autistic populations, and to propose an actionable, multi-stakeholder public health implementation framework that integrates Medical Laboratory Science (MLS), primary care delivery, and Community Health Worker (CHW) navigation.

Methods: A systematic scoping review was conducted following PRISMA-ScR guidelines across seven bibliographic databases (PubMed, Embase, CINAHL, PsycINFO, Web of Science, Scopus, Cochrane Library) and public health repositories. Eligible studies evaluated diagnostic access, behavioral desensitization, micro-sampling innovations, psychotropic surveillance protocols, or care navigation models in autistic populations. Evidence was mapped onto Link and Phelan’s Fundamental Causes Model, the SEIPS ergonomic framework, and the Consolidated Framework for Implementation Research (CFIR) to formulate an integrated MLS-PCP-CHW care delivery triad.

Results: Pre-analytical venipuncture avoidance affects 52% of autistic adults, with 95.5% identifying acute procedural pain as the primary obstacle. Structured behavioral desensitization programs significantly increase blood draw compliance from 85.4% to 96.6% (p = 0.03). Touch Activated Phlebotomy (TAP) capillary micro-sampling demonstrates significantly lower pain scores than traditional venipuncture (p = 0.006) and equivalent pain tolerability between autistic and neurotypical participants (p = 0.795), while producing minimal analytical bias (0.44 ng/mL) and high repeatability (ICC = 0.888) across metabolic analytes. Interdisciplinary Team Review (IRT) monitoring models achieved an average of 15.6 psychotropic medication dosage reductions and 2 complete eliminations annually while maintaining behavioral stability and active caregiver engagement (94.6%).

Conclusion: Eliminating pre-analytical phlebotomy bottlenecks through an integrated MLS-PCP-CHW public health framework ensures safe metabolic surveillance, reduces diagnostic disparities, and promotes equitable, neurodiversity-affirming preventive healthcare across the lifespan.

PDF